Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A personalized mRNA cancer vaccine just delivered a major win. The phase III INTerpath-001 trial found that combining intismeran autogene with pembrolizumab reduced the risk of recurrence or death by 42% in patients with resected stage IIB-IV melanoma, compared to pembrolizumab alone. Experts are calling it "the beginning of an entirely new way of treating cancer."
A personalized mRNA cancer vaccine just delivered one of oncology's most anticipated results. The phase III INTerpath-001 trial showed that intismeran autogene — an individualized neoantigen therapy — combined with pembrolizumab (Keytruda) cut the risk of recurrence or death by 42% in patients with completely resected stage IIB-IV melanoma, compared to pembrolizumab alone. Results were released early after an online data leak ahead of their scheduled presentation at the ESMO Congress in Madrid.
The vaccine works by encoding up to 34 neoantigens tailored to the unique mutational signature of each patient's tumor, essentially training the immune system to recognize and attack cancer cells specific to that individual. Experts are calling the findings a potential "foundational shift" in how earlier-stage melanoma is treated — and possibly a blueprint for tackling other cancer types.
By the Numbers:
Why it matters: This is the first phase III trial to demonstrate that a personalized mRNA cancer vaccine can meaningfully improve outcomes in melanoma — a proof of concept that could reshape adjuvant cancer treatment well beyond this single tumor type. Longer follow-up is still needed to assess overall survival.
